Mustang Bio, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Related Party Agreements (Narrative) (Details)

Related Party Agreements (Narrative) (Details)						1 Months Ended	12 Months Ended
Related Party Agreements (Narrative) (Details)	Jan. 01, 2026 shares	Jan. 01, 2025 shares	Jan. 01, 2017 USD ($) shares	Jul. 26, 2016 USD ($) shares	Mar. 13, 2015	Jul. 31, 2016	Dec. 31, 2025 USD ($) item shares	Dec. 31, 2024 USD ($) shares
Related Party Agreements
Preferred stock voting rights multiplier				1.1
Proceeds from warrant exercises							$ 7,145,000	$ 3,523,000
General and administrative							3,948,000	4,135,000
At the Market Offering
Related Party Agreements
Proceeds from issuance of common shares							$ 600,000	2,600,000
Class A Preferred Shares
Related Party Agreements
Shares issuable on conversion, per share converted \| shares				1
Fortress Biotech, Inc
Related Party Agreements
Proceeds from related party debt				$ 2,000,000
Founders agreement term				15 years
Agreement renewal term				1 year
MSA agreement term					5 years
MSA agreement renewal term					5 years
Equity fee, period for payment after financing							5 days
Cash fee, period for payment							90 days
Change in control fee, multiplier \| item							5
Change in control fee, measurement period							12 months
Paid in kind dividend, period prior to payment date for measuring ownership				1 day
Stock dividend (as a percent)				2.50%
Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses							50.00%
Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses							50.00%
Expenses from related party transaction							$ 500,000	$ 500,000
Net assets threshold							100,000,000
Consulting fee when net assets exceed threshold							$ 1,000,000
Percentage of fully diluted equity							2.50%	2.50%
Change in control fee, specified rate component							4.50%
Cash fee (as a percent)							4.50%
Equity fee payable in shares (as a percent)							2.50%
Shares issued for services (in shares) \| shares		69,046					127,140	23,450
Annual consulting fee							$ 500,000
Fortress Biotech, Inc \| October registered direct offering
Related Party Agreements
Proceeds from warrant exercises								$ 4,000,000
Fortress Biotech, Inc \| At the Market Offering
Related Party Agreements
Shares issued for services (in shares) \| shares							1,361	3,509
Proceeds from issuance of common shares							$ 600,000	$ 2,600,000
Fortress Biotech, Inc \| February 2025 Equity Offering
Related Party Agreements
Proceeds from issuance of common shares							8,000,000
Fortress Biotech, Inc \| February 2025 Equity Offering \| Series C-2 Warrants
Related Party Agreements
Proceeds from warrant exercises							7,100,000
Fortress Biotech, Inc \| May 2024 Equity Offering
Related Party Agreements
Proceeds from issuance of common shares								4,000,000
Fortress Biotech, Inc \| June 2024 Registered Direct Offering
Related Party Agreements
Proceeds from warrant exercises								2,500,000
Fortress Biotech, Inc \| Class A Preferred Shares
Related Party Agreements
Conversion of Stock, Shares Issued \| shares				250,000
Percentage of fully diluted equity						2.50%
Fortress Biotech, Inc \| Class B common shares
Related Party Agreements
Number of shares converted \| shares				7,250,000
Fortress Biotech, Inc \| Common shares
Related Party Agreements
Conversion of Stock, Shares Issued \| shares				9,333
Subsequent events \| Fortress Biotech, Inc
Related Party Agreements
Shares issued for services (in shares) \| shares	278,385
Parent Company \| Founders Agreement \| Fortress Biotech, Inc
Related Party Agreements
Percentage of fully diluted equity		2.50%
Research and development for expense acquired							$ 300,000	$ 600,000
Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]							Research and Development Expense (Excluding Acquired in Process Cost), Net	Research and Development Expense (Excluding Acquired in Process Cost), Net
General and administrative							$ 400,000	$ 300,000
Parent Company \| Subsequent events \| Founders Agreement \| Fortress Biotech, Inc
Related Party Agreements
Percentage of fully diluted equity	2.50%
Director
Related Party Agreements
Annual consulting fee							$ 50,000
Director \| Restricted stock award
Related Party Agreements
Share-based compensation arrangement by share-based payment award \| shares							0	0
Director \| Maximum
Related Party Agreements
Number of shares granted as compensation \| shares							10,000
Value of shares granted as compensation							$ 50,000
Director \| Dr Lindsay A. Rosenwald
Related Party Agreements
Expenses from related party transaction							50,000	$ 50,000
Director \| Mr. David Jin
Related Party Agreements
Expenses from related party transaction							50,000	12,500
Board of Directors Chairman
Related Party Agreements
Expenses from related party transaction							$ 60,000	$ 60,000
Annual consulting fee			$ 60,000
Board of Directors Chairman \| Restricted stock award
Related Party Agreements
Share-based compensation arrangement by share-based payment award \| shares							0	0
Board of Directors Chairman \| Maximum
Related Party Agreements
Number of shares granted as compensation \| shares			10,000
Value of shares granted as compensation			$ 50,000